OXBRYTA

This brand name is authorized in Austria, Estonia, France, Croatia, Ireland, Italy, Lithuania, Poland, United States

Active ingredients

The drug OXBRYTA contains one active pharmaceutical ingredient (API):

1 Voxelotor UNII 3ZO554A4Q8 - VOXELOTOR

Voxelotor is a haemoglobin S (HbS) polymerisation inhibitor that binds to HbS with a 1:1 stoichiometry and exhibits preferential partitioning to red blood cells (RBCs). By increasing the affinity of Hb for oxygen, voxelotor demonstrates dose-dependent inhibition of HbS polymerisation. Voxelotor inhibits RBC sickling and improves RBC deformability. Read about Voxelotor

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
OXBRYTA Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC
OXBRYTA Film-coated tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
B06AX03		B Blood and blood forming organs → B06 Other hematological agents → B06A Other hematological agents → B06AX Other hematological agents
Discover more medicines within B06AX03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1875999
Country: FR	Base de données publique des médicaments	Identifier(s): 62137714
Country: IT	Agenzia del Farmaco	Identifier(s): 049971017
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1094267
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100465932
Country: US	FDA, National Drug Code	Identifier(s): 72786-101